Mesoblast Limited (ASX:MSB)

Market Cap	3.41B
Revenue (ttm)	26.23M
Net Income (ttm)	-155.80M
Shares Out	1.28B
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,575,298
Average Volume	4,227,165
Open	2.610
Previous Close	2.540
Day's Range	2.590 - 2.680
52-Week Range	1.515 - 3.370
Beta	0.76
RSI	59.26
Earnings Date	Nov 18, 2025

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 81
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSB

Financial Performance

In 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Financial numbers in USD